MOACM
APLS

Mutual of America Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Mutual of America Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,728
Closed -$472K – 1451
2026
Q1 		$472K Buy
+11,728
New +$253K 0.01% 1072
2024
Q4 		– Sell
-27,211
Closed -$785K – 1442
2024
Q3 		$785K Sell
27,211
-255
-0.9% -$9.44K 0.01% 1062
2024
Q2 		$1.05M Sell
27,466
-1,188
-4% -$53.8K 0.01% 1018
2024
Q1 		$1.68M Sell
28,654
-2,328
-8% -$148K 0.02% 957
2023
Q4 		$1.85M Sell
30,982
-10,532
-25% -$534K 0.02% 926
2023
Q3 		$1.58M Sell
41,514
-2,470
-6% -$108K 0.02% 953
2023
Q2 		$4.01M Buy
43,984
+17,132
+64% +$1.48M 0.05% 589
2023
Q1 		$1.77M Sell
26,852
-1,237
-4% -$71.4K 0.02% 940
2022
Q4 		$1.45M Buy
28,089
+378
+1% +$20K 0.02% 977
2022
Q3 		$1.89M Buy
+27,711
New +$1.64M 0.03% 870

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mutual of America Capital Management's APLS Position: Q2 2026 in Review

Mutual of America Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 11,728 shares — an estimated $472K sold.

Mutual of America Capital Management first reported a position in APLS in Q3 2022 and held it in 10 quarters. The position peaked at $4.01M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Mutual of America Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mutual of America Capital Management sold 11,728 Apellis Pharmaceuticals shares in Q2 2026, an estimated $472K.
  • Mutual of America Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 10 quarters.
  • Mutual of America Capital Management's Apellis Pharmaceuticals position peaked at $4.01M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.